Tag: Therapeutics
Ipsen joins forces with Skyhawk Therapeutics in rare neurological diseases – 04/22/2024 at 09:52
(AOF) – Ipsen announces the signing of a research collaboration agreement with Skyhawk Therapeutics aimed at targeting RNA in rare neurological diseases. The biotech specifies that Skyhawk’s technology platform makes…
Ipsen and Skyhawk Therapeutics announce the signing of a research collaboration agreement aimed at targeting RNA in rare neurological diseases – 04/22/2024 at 07:00
Ipsen Enters into Option Agreement for Exclusive Worldwide Rights for Successful Candidates in Collaboration Once the development candidate has been validated, Ipsen will be responsible for its continued development and…
Ipsen and Skyhawk Therapeutics agree on RNA targeting in rare neurological diseases – 04/22/2024 at 07:09
Ipsen SA IPN.PA: * IPSEN AND SKYHAWK THERAPEUTICS ANNOUNCE THE SIGNATURE OF A RESEARCH COLLABORATION AGREEMENT AIMING AT RNA TARGETING IN RARE NEUROLOGICAL DISEASES * IPSEN ENTERS INTO AN OPTION…
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected in the 3rd quarter of 2024 This study makes it possible to…
PHAXIAM Therapeutics announces the recruitment of the first patient in the phase 1 study in infective endocarditis caused by Staphylococcus aureus – 04/15/2024 at 07:30
The study plans the inclusion of 12 patients in 5 French clinical centers The first results are expected on 3 th quarter 2024 This study makes it possible to evaluate…
PHAXIAM Therapeutics announces the filing of its 2023 Universal Registration Document (URD) - 04/05/2024 at 6:00 p.m.
Lyon (France) and Cambridge (MA, US), April 5, 2024 – 6:00 p.m. CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135) biopharmaceutical company developing innovative treatments against severe and resistant bacterial infections…
Phaxiam Therapeutics: an analyst adjusts the cursor
By Hector Chaunu Published on 04/03/2024 at 10:49 a.m. Photo credit © CrostaPics (Boursier.com) — Phaxiam Therapeutics…
Seelos Therapeutics’ ALS treatment fails in mid-stage study – 03/19/2024 at 3:30 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) (Added CEO comment to paragraph 7, background throughout article; updated action progress) Seelos Therapeutics’ experimental ALS drug SEEL.O failed to meet the…
Merck completes the acquisition of Harpoon Therapeutics – 03/11/2024 at 1:51 p.m.
(AOF) – Merck today announced the completion of the acquisition of Harpoon Therapeutics. The American group announced on January 8 the purchase of this oncology company for $23 per share…
PHAXIAM Therapeutics announces the completion of the voluntary withdrawal of its “American Depository Shares” from the Nasdaq Stock Market – 03/11/2024 at 07:00
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 7:00 a.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections,…
PHAXIAM Therapeutics announces the completion of the voluntary withdrawal of its “American Depository Shares” from the Nasdaq Stock Market – 03/11/2024 at 07:00
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 7:00 a.m. CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments against resistant bacterial infections,…
Denali Therapeutics jumps 30% after $500 million PIPE financing – 02/27/2024 at 7:46 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) February 27 – ** Denali Therapeutics Inc. shares. DNLI.O jumped 31 percent to $22.13, its highest level of the year, on Tuesday…